Rationale: Mechanisms underlying diastolic dysfunction need to be better understood. Objective: To study the role of titin in diastolic dysfunction using a mouse model of experimental heart failure induced by transverse aortic constriction.
A ltered hemodynamics, such as elevated blood pressure and aortic valve diseases, lead to pathological cardiac hypertrophy and ultimately heart failure (HF), characterized by left ventricular dilation, decreased contractility, and increased myocardial stiffness. 1 Although the molecular mechanisms that underlie decreased contractility have been investigated extensively, the molecular basis of diastolic dysfunction is less well-understood. [2] [3] [4] Understanding the mechanisms that govern diastolic dysfunction is important for understanding a wide range of cardiac diseases, including heart failure with preserved ejection fraction (HFpEF), a prevalent disease without effective therapy. 4 -7 The extracellular matrix (ECM) is often considered to dominate passive myocardial stiffness, but work focused on the intracellular protein titin has shown that titin is also important for generating passive muscle stiffness. 5 Titin spans from Z-disk to M-line and is extensible in the I-band region of the sarcomere, where it functions as a molecular spring that develops passive force in sarcomeres stretched beyond their slack length (Ϸ1.9 m). 8 Differential splicing results in two main isoforms: the N2B isoform that is stiff (Ϸ3.0 MDa) and the larger N2BA isoform that is more compliant (Ϸ3.4 MDa). 9 These isoforms are coexpressed in the adult heart, with alterations in their expression ratio giving rise to changes in myocardial stiffness. 10 In addition, titin phosphorylation also alters myocardial stiffness. Both protein kinase A (PKA) 11 and protein kinase G (PKG) 12 phosphorylate titin (most likely at the same site in the N2B spring element 12 ) and reduce myocardial stiffness (increased compliance). Evidence suggests that hypophosphorylation of PKA/PKG sites on titin contribute to reduced compliance in HFpEF patients. 13 Recently, it was found that titin is also a target of protein kinase C (PKC)␣, and that PKC␣ phosphorylation of two conserved serines in the proline glutamate valine lysine (PEVK) region of titin (S26 and S170 in the PEVK of the N2B cardiac titin isoform) increases cardiac stiffness. 14 -16 Here, we studied titin in mice with HF induced by transverse aortic constriction (TAC) and focused on myocardial passive stiffness, titin isoform expression, and titin phosphorylation. We found a large increase in myocardial stiffness in HF that can be explained in large part by hyperphosphorylation of titin spring elements.
Methods

TAC
We used 8-week-old male C57BL/6J mice obtained from The Jackson Laboratory (Bar Harbor, ME). The aortic banding procedure used a 27-gauge (0.42-mm outer diameter) needle to constrict the aorta; details are explained in the Supplemental Methods (available online at http://circres.ahajournals.org). TAC and sham mice were evaluated 8 weeks after surgery using echocardiography. After this, mice were euthanized, weighed, and left ventricle (LV) weight (LVW) and lung weights were determined. Hearts were immediately dissected, LV papillary muscles were removed, and the LV was split into bilateral halves that were either frozen or stored in RNAlater. TAC animals were divided into two groups based on the LVW/body weight (BW) ratio (HF, 4.25-6.75 mg/g; congestive heart failure [CHF], Ͼ6.75 mg/g) and lung weight/BW ratio (HF, 4.5-12 mg/g; CHF, Ͼ12 mg/g; Figure 1 ), because LV mass and pleural edema both correlate with degree of HF development. 17 Additionally, the two experimental groups had changes in calcium-handling proteins SERCA2a, PLB, pPLB, pTnI, and myosin heavy chain expression (Supplemental Figures I and II) that are similar to reported previously for TAC mice (Supplemental Materials and Methods). Experiments were approved by the University of Arizona Institutional Animal Care and Use Committee and followed the U.S. National Institutes of Health Using Animals in Intramural Research guidelines for animal use.
Echocardiography
Echocardiography was performed as described 18 using a Vevo 770 System (Visual-Sonics). Details provided in Supplemental Materials and Methods.
Gel Electrophoresis
SDS-agarose electrophoresis was performed as previously described, 19 with additional details in the Supplemental Materials and Methods.
Phosphorylation Assays
Detection of LV protein phosphorylation and recombinant protein was by protein labeling ( 32 P), phosphoprotein stain (Pro-Q diamond), and Western blots probed with phospho-specific antibodies (PS26 GL Biochem and PS170 Genscript) against pS26 and pS170 of titin found in the PEVK element and against various calcium handling and myofibrillar proteins (Supplemental Materials and Methods).
Microarray Studies
The titin exon microarray experiments were performed as described previously. 20 
Measurement of Passive Tension
Small muscle strips were attached to a motor and a force transducer via aluminum clips and passive tension was measured in relaxing solution. Sarcomere length (SL) was measured online by laser diffraction. Passive stiffness was determined from the slope of the linear regression line that was fit to the passive tension SL data in the 1.95-to 2.05-m SL range, which encompasses the physiological SL range. 21 For the protein phosphatase-1 (PP1) experiments, muscles were incubated with PP1 (0.5 U/L) for 2 hours, and passive stiffness was measured at 20-minutes intervals.
Statistics
Data are presented as meanϮSEM. Group significance was defined using ANOVA followed by Tukey-Kramer multiple comparison test. SL significance was determined using two-way ANOVA. Student t test was used in Figure 6A (inset). PϽ0.05 was considered significant.
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Results
TAC-induced HF
Using echocardiography and tissue weight analysis, we evaluated hypertrophy, LV chamber dimensions, and LV function in sham-operated (control, nϭ12), HF (nϭ10), and CHF (nϭ6) mice. The LVW was significantly increased by 34% in HF and 92% in CHF and when normalized to BW. LVW/BW ratios were significantly increased by 36% and 226%, respectively (Supplemental Table I and Figure 1A ). Lung weight/BW was also significantly increased in both HF and CHF, with a modest 20% increase in HF and a 346% increase in the CHF group (Supplemental Table I and Figure 1B) . Echocardiography confirmed the hypertrophy and also revealed increased chamber dimensions in both experimental groups with changes that were most severe in the CHF mice (Supplemental Table II and Figure 1C ). Fractional shortening (%) and ejection fraction (%) were both significantly reduced in the two experimental groups (Supplemental Table II ). We measured expression of ␤-myosin heavy chain, an indicator of HF, 22 and found a trend toward an increase in ␤-myosin heavy chain in HF mice and a significant increase in CHF mice (Supplemental Figure I) . We also found trends toward a reduction in SERCA2a and PLB expression and decreased phoshorylation levels of S23/24 of cTnI and S16 of PLB in HF and significant changes in CHF (Supplemental Figure II A-D). Thus, the combined data from tissue weights, echocardiography, and protein data all reveal that the TAC mice had HF, with the most deleterious changes in the CHF group. Doppler echocardiography was used to measure the ratio of peak transmitral early (E) and late (A) diastolic velocities, and the deceleration time of the E wave (DT). The E/A ratio was significantly increased by 68% in the HF group and by 207% in the CHF group ( Figure 1D ), changes that are attributable to a modest increase in E and a more severe reduction in the A parameter (Supplemental Table II ). These changes are likely to reflect increased ventricular chamber stiffness in both experimental groups, with the largest increase in CHF. Consistent with this hypothesis is the reduced DT in CHF (DT is considered to be inversely related to LV chamber stiffness 23 ). Heart rate (HR) during these measurements was not different between the groups (Supplemental Table II ); therefore, it is unlikely that measured differences in diastolic function are attributable to unequal HR.
Tissue Mechanics and Passive Stiffness in HF and CHF TAC Mice
Mechanical experiments were performed on skinned myocardial tissue. Maximal active tension was significantly reduced in both HF (nϭ5) and CHF (nϭ4) heart failure groups as compared to controls (nϭ4) (34.2Ϯ1.5 mN/mm 2 and 30.3Ϯ2.4 mN/mm 2 , respectively, vs 41.8Ϯ2.6 mN/mm 2 in controls; Table) . This active tension reduction is consistent with other studies of rodents with experimental CHF (30% reduction in tension in CHF rats 24 vs 28% in our work in CHF mice) and might be attributable to increased PKC␣ signaling that causes hyperphosphorylation of myofilament proteins. 24 Passive tension was measured by stretching the skinned tissue in relaxing solution from the slack sarcomere length (SL) to a maximal SL of 2.15 m. In pilot studies, the maximal SL at the end of the stretch was 2.3 m, but this resulted in irreversible damage in both the HF and CHF tissues, as revealed by reduced passive tension in subsequent stretches. This phenomenon was avoided by limiting the maximal SL to 2.15 m. Passive tension ( Figure 2A , left and right panels) and passive stiffness (slope of passive tension-SL relation in the physiological SL range; 21 Table) were significantly increased in HF and CHF mice, with higher values in HF. To establish whether this increase involves residual actomyosin interaction, we performed experiments in the presence of 20 mmol/L BDM, a known inhibitor of actomyosin interaction. BDM had no effect on passive tension (results not shown), suggesting that the increased passive tension in HF and CHF is attributable to only passive material properties of the myocardium. It is also important to highlight that although differences in calcium handling proteins exist, in both expression level and phosphorylation status (Supplemental Figure II) , these changes are unable to explain our findings considering that the experiments were performed on muscle that had been demembranated with detergent (Triton X-100). To evaluate whether elevated passive tension might be attributable to the oxidizing conditions that are known to exist in HF, 25 and which are know to also affect titin, 26 we also performed experiments in which we increased the level of the reducing agent DTT in the relaxing solution (from 1 mmol/L to 10 mmol/L), but again found no effects on passive tension (Supplemental Figure III) .
To determine the specific contributions of titin vs collagen to passive stiffness, muscles were treated with high concentrations of KCl and KI to extract thick and thin filaments and therefore remove the sarcomeric anchors of titin. This abolishes the ability of titin to develop passive tension but leaves the ECM-based passive tension intact. 27, 28 KCl/KI extraction revealed that ECM-based passive tension ( Figure 2B , left and right panels) and stiffness (Table) in HF and CHF mice are significantly increased, consistent with the known presence of fibrosis in TAC-induced HF. 29 Subtracting ECM-based tension from total tension shows that both HF and CHF mice had significantly greater titin-based passive tension ( Figure 2C , left and right panels) and stiffness (Table) compared to controls. Interestingly, titin-based passive tension and stiffness in CHF were reduced relative to HF. Thus, increased collagen-based and titin-based passive tensions are responsible for increased passive tension in TAC-induced HF and CHF. Supplemental Figure IV compares the relative contribution of titin and collagen to overall passive tension. In all three groups (control, HF, and CHF), titin is the main contributor to passive tension. Titin contributes approximately 75% and ECM contributes approximately 25% in both controls and HF mice, whereas the contributions of titin declines in CHF to approximately 60% and ECM-based tension increases to approximately 40% of total.
Differential Splicing and Phosphorylation of Titin
Differential splicing results in the expression of two main cardiac titin isoforms, the stiff N2B and the larger and more compliant N2BA isoforms. 10 Using high-resolution gel electrophoresis, we evaluated the titin isoform expression ratio in TAC mice with the expectation that upregulation of the stiff N2B isoform might explain the increased titin-based passive tension of the HF and CHF tissues. Consistent with earlier studies, 30 the control animals have a N2BA:N2B expression ratio of approximately 0.2 ( Figure 3A, B) , confirming that the shorter stiffer N2B isoform is dominant in the mouse heart. The HF and CHF mice showed an increase in the more compliant N2BA isoform ( Figure 3B , Supplemental Table  III ) that correlates with the LVW/BW ratio (PϽ0.001; Figure  3C ). The increased expression of the compliant N2BA isoform is opposite of what was expected from the measured increase in titin-based passive stiffness. To test whether this discrepancy might be attributable to changes in expression levels of titin, we determined the relative amount of titin per milligram of tissue and the amount of titin relative to the expression level of myosin heavy chain. The HF and CHF groups were not significantly different in their level of titin expression (Supplemental Table III ). Finally, we also evaluated the titin degradation product, T2, and found no significant change after aortic constriction (Supplemental Table III) . Thus, the only significant change that was found is the upregulation of the compliant N2BA isoform at the expense of the stiff N2B isoform. Because this finding was unexpected, we also evaluated titin expression at the transcript level by performing a titin exon expression analysis using a homemade microarray on which all 358 exons found in the mouse are represented. We found significant upregulation of a large group of PEVK and Ig exons in CHF tissues compared to controls (Supplemental Table IV ), confirming that CHF mice express a larger titin than control heart tissue.
Because the stiffness of titin also can be varied through phosphorylation, with PKA and PKG phosphorylation decreasing stiffness 11, 12, 31 and PKC phosphorylation increasing stiffness, 14, 15 we also evaluated the phosphorylation levels of titin. Back phosphorylation assays revealed reduction in 32 P incorporation in response to phosphorylation by PKA ( Figure  4 ) that indicate hyperphosphorylation of HF and CHF mice, changes that are expected to lower passive stiffness. 11, 12, 31 Recently, PKC␣ was shown to phosphorylate titin specifically at S11878 and S12022 (S26 and S170, respectively, in the PEVK region of the N2B cardiac isoform), with evidence that suggests that phosphorylation of S26 induces a large increase in passive stiffness. 14,15 Therefore, we developed phospho-specific antibodies (pS26 and pS170) that positively recognize PKC␣ phosphorylation of both recombinant PEVK protein and mouse myocardium. Validation of these new antibodies with recombinant proteins in which S26 and S170 were mutated showed that the antibodies are specific to the phospho-S26 or phospho-S170, and that PP1 dephosphorylates these sites (Supplemental Figure V) . We also showed that the popular phospho-protein stain Pro-Q diamond does not specifically detect the phosphorylated PEVK sites, but that Pro-Q diamond can be used to detect PKA phosphorylation of the N2B element (Supplemental Figure VI) . Thus, phospho-specific antibodies are required to study PKC phosphorylation. The phospho-specific antibodies were used in a Western blot analysis of LV proteins, and this showed in both HF and CHF tissues a large reduction in phosphorylation of the S170 site of PEVK ( Figure 5A ); interestingly we found increased PKC␣ phosphorylation of the S26 site of PEVK ( Figure 5B) .
To elucidate the contribution of PKC␣ phosphorylation to the increased titin-based passive stiffness in heart failure LV tissue, control and HF samples were incubated in PP1 (0.5 U/L) for 2 hours, with tensions measured both before and after PP1 treatment. Baseline titin-based passive tension ( Figure 6A ) was increased in HF samples, consistent with results of Figure 2 . After PP1 treatment, titin-based passive tension was unchanged in control LV. However, incubation of HF LV in PP1 resulted in a significant decrease in passive tension ( Figure 6A ) and stiffness ( Figure 6A, inset) . We performed a phosphorylation analysis of S26 and S170 using the samples from the mechanical studies and found after PP1 treatment no differences between control and HF samples ( Figure 6B ). Thus, PP1 treatment normalizes both differences in phosphorylation of S26 and S170 and in titin-based passive stiffness.
Discussion
There is heightened awareness that it is critically important to fully understand the underlying mechanisms of diastolic dysfunction because of its clinical importance and absence of effective therapies. 6, 7, 32 In this work, we studied a TACinduced HF mouse model, we segregated mice in HF and CHF groups, and we performed a myocardial passive stiffness analysis with a focus on titin. A large increase in passive myocardial stiffness was found in both the HF and CHF groups, and it was most severe in HF and somewhat less severe in CHF mice. The data further indicate that heart failure-induced fibrosis results in an increase in ECM-based passive stiffness and, importantly, that titin plays a major role in increased myocardial passive stiffness. The contribution of titin to passive myocardial stiffness is greatly increased in HF mice, relative to that of sham mice, and this might be attributable to hyperphosphorylation of a PKC site in the PEVK region of titin. In CHF mice, titin-based stiffness is increased as well, but not as much as in HF mice, which can be explained by the increased expression of the compliant N2BA titin that we found.
Total passive myocardial stiffness was increased approximately 2.5-fold in the HF mice and approximately two-fold in the CHF mice ( Figure 7A ). The total stiffness increase in the HF group is slightly higher than recently reported by Bradshaw et al 33 in papillary muscle of TAC mice (Ϸ1.6-fold increase), which might be explained by the more severe hypertrophy in our study. ECM-based stiffness was found to be approximately three-fold higher in the HF group and approximately four-fold higher in the CHF group than in the sham mice (Table) . These increases can be explained by the increased ECM collagen content and increased collagen cross-linking that are known to take place in the TAC mouse model. 33 The increase in titin-based stiffness is consistent with the recently reported increased passive tension of skinned cardiac myocytes isolated from mice with severe TAC. 34 The increase in passive material properties of the myocardium will increase diastolic stiffness of the LV wall in HF and CHF. Diastolic stiffness can also be increased by incomplete relaxation attributable to, for example, the wellknown reduction in SERCA2a levels in CHF (Supplemental Figure IIA) and the increased calcium sensitivity of the myofilaments that some 34 (but not others 24 ) have reported. Increased calcium sensitivity is unlikely to explain the increased stiffness that we found in skinned muscle because measurements were made in relaxing solution and, furthermore, the actomyosin inhibitor BDM had no effect on passive stiffness. In summary, passive myocardial stiffness of HF and CHF mice is increased because of changes in both ECM and titin, and this increase is expected to contribute to elevated diastolic stiffness.
A possible explanation for the increase in titin-based stiffness is the recently discovered disulfide cross-linking that occurs in the N2B element under oxidative stress, 26 a state that is common during heart failure. 25 Because such crosslinking increases titin-based passive stiffness, 26 we tested the possibility that the increase in stiffness in HF mice was attributable to increased disulfide cross-linking bonding by performing experiments under reducing conditions (10 mmol/L DTT). Results indicate that oxidation of titin was not the cause of the increase in passive stiffness in heart failure. Titin-based passive stiffness can be regulated by differential splicing of titin; titin molecules with a longer extensible region increase sarcomere compliance. Two cardiac titin isoforms are coexpressed within the sarcomere, the N2B and N2BA isoforms with short (stiff) and long (compliant) extensible regions, respectively, and their expression ratio is an important determinant in titin-based passive stiffness. 10 Furthermore, it has been demonstrated in a canine tachycardia-induced model of dilated cardiomyopathy 35 and Figure 6 . A, Titin-based passive tension and phosphorylation of S26 and S170 after dephosphorylation with protein phosphatase I (PP1). Before PP1 treatment, passive tension is significantly higher in heart failure samples (confirming results of Figure 2) . Whereas tensions were unchanged in control (Ctrl) samples after PP1 treatment, heart failure (HF) samples had a significant reduction in their passive tensions. Inset shows percent change in titin-based passive stiffness (slope of passive tension, sarcomere length [SL] relation in 1.95 to 2.05 m SL length range) after PP1 treatment. B, Western blot analysis of PS26 and PS170 titin sites in Ctrl and HF samples after PP1 treatment (same samples as in A). WB normalized to Ponceau S-based protein levels and results of control samples set to 100%. No differences in phosphorylation levels are detected after PP1 treatment. *Significant vs Ctrl (PϽ0.05). **Significant vs Ctrl (PϽ0.01). #HF significant vs HF ϩ PP1 (PϽ0.05). Table) . B, Schematic showing effects on passive stiffness of increase in S26 phosphorylation (top) and upregulation of N2BA titin (bottom).
in spontaneously hypertensive rats 36 that a decrease in the expression of N2BA titin is accompanied by an increase in myocardial passive stiffness. Therefore, we hypothesized that the increase in titin-based myocardial stiffness might be attributable to increases in the stiffer N2B isoform, resulting in more passive tension when stretched to a specific sarcomere length. In contrast to the expected increase in expression level of the stiffer N2B isoform, both protein ( Figure 3 ) and transcript (Supplemental Table IV ) data showed that the compliant N2BA isoform of titin actually increases its expression level ( Figure 3B ). Although these data are opposite from what we expected, the result does correspond to isoform changes previously seen in human patients with ischemic human heart disease, 37 dilated cardiomyopathy, 38, 39 HFpEF, 13 and aortic stenosis. 13 Thus, although differential splicing is a prominent mechanism for altering passive stiffness, the change in splicing that occurs in HF cannot explain the increased titin-based stiffness that we found and, in fact, it is excepted to lower passive stiffness instead.
The stiffness of titin can also be altered through phosphorylation, with disparate effects via the PKA/PKG and PKC pathways. Both PKA and PKG have been found to phosphorylate the cardiac-specific N2B element and reduce stiffness of titin. 11, 12 However, PKC␣ phosphorylates the PEVK region of titin and this increases passive stiffness. [15] [16] Recent studies have shown that the PKA/PKG pathway is important in explaining the increased passive stiffness of myocytes in HFpEF patients in whom a reduction has been found in the phosphorylation level of PKA/PKG sites in titin and in whom treating the skinned cardiac myocytes from HFpEF patients with PKA lowers passive stiffness toward that of the control cells. 13 Therefore, we thought that the observed shift from the stiffer N2B isoform to a more compliant N2BA isoform in our study could be thought of as a compensatory mechanism for increased myocardial stiffness, and that a reduction in the basal phosphorylation level of PKA accounts for the increased stiffness. Yet again, in contrast to our hypothesized results, PKA phosphorylation analysis showed hyperphosphorylation of PKA sites (Figure 4 ). Similar to the increased compliant isoforms that we found, these changes are predicted to decrease passive tension. One hypothesis for why these results are different from those in the human study discussed is as follows. Recently, Hamdani et al 40 reported differences in phosphorylation levels of regulatory proteins in a variety of animals ranging from mice to human. Data revealed that the basal phosphorylation level is speciesdependent and that reduced PKA-mediated phosphorylation was found only in end-stage failing human myocardium. We hypothesize that mice with HF are less sensitive to defects in ␤-adrenergic signaling than humans and speculate that this explains why the PKA sites of titin are not hypophosphorylated in our study. Hyperphosphorylation of PKA sites might potentially be explained by the recent finding that the PKA sites of titin in the N2B region of titin can also be phosphorylated by PKG 12 and the elevated PKG activity in TAC mice that has been reported. 41 Clearly, myofilament protein phosphorylation is a complex process with alternative pathways that can have similar or disparate results.
Recently, our laboratory has found that titin is also a target of PKC␣ and that PKC␣ phosphorylation of titin increases cardiac stiffness. 15, 16 Two sites were found in the PEVK region of titin (S26 and S170 in the PEVK region of the N2B isoform) that are present in all known cardiac and skeletal muscle titin isoforms. We produced phospho-specific antibodies against the two sites (Supplemental Figure V) and used them to assay site-specific phosphorylation events within titin. The results showed hypophosphorylation of the S170 PKC␣ site and hyperphosphorylation of S26 ( Figure 5 ). Because we have shown that PKC phosphorylation increases passive stiffness both at the single molecule 14 and single cell levels, 15, 16 it is possible that the hyperphosphorylation of S26 plays an important role in the increased titin-based stiffness. The hyperphosphorylation of PKC sites is consistent with the increased expression levels of PKC␣ that have been found in mice subjected to TAC. 41 That hyperphosphorylation of titin is a mechanism for increased passive stiffness is supported by the dephosphorylation studies in which passive stiffness was measured before and after PP1 treatment ( Figure 6 ) and that showed that PP1 significantly lowered the high passive stiffness of HF myocardium.
It is interesting that two phosphorylation sites 144 residues apart (PEVK S26 and S170) and phosphorylated by the same kinase have such different phosphorylation levels in HF myocardium. Previous studies on PKC phosphorylation sites showed that PKC␣ prefers basic residues N-terminal and C-terminal to the phosphorylation site. 42 These studies also indicate that PKC preferentially phosphorylates serines with basic residues within three amino acids of both the C-terminal and N-terminal sides of it. Based on these studies, PKC would have a stronger affinity toward S26 than S170 because of the closer proximity of the neighboring basic amino acids (lysine [K] and arginine [R]; Supplemental Figure VII) , which is consistent with the experimental PKC phosphorylation data on recombinant PEVK proteins. 15 Other possibilities exist as well, such as protein binding at or near S170.
The PP1 experiments lowered passive stiffness ( Figure 6 ), and because PKA/PKG and PKC sites have been shown to be dephosphorylated by PP1, 12,15 either one or both might explain the passive stiffness reduction. However, dephosphorylation of PKA sites increases passive stiffness, 12 and the S170 PKC site already has a low phosphorylation level before PP1 treatment ( Figure 5B ) and, thus, they are unlikely candidates. However, S26 is more promising because single molecule studies have shown that it is more important than S170 in determining passive stiffness, 14 and S26 is hyperphosphorylated in HF tissue, where stiffness is high and its dephosphorylation (PP1 treatment) is expected to cause a reduction of stiffness, as we found. Thus, phosphorylation of S26 is likely to be crucial in determining the contribution of titin to myocardial stiffness. The significant increase in phosphorylation of S26 in HF is consistent with the increased PKC␣ activity that has been reported to occur in CHF rats. 24 Considering that the PKC␣-based passive stiffness modulation pathway was only discovered recently, it is unknown whether our findings in the HF mouse model extrapolate to different disease models. It is interesting to note, however, that a recent HFpEF study reported that cellular passive stiffness after PKA treatment reduced passive tension but remained higher than in control cells (in fact, N2BA titin was upregulated, similar to what we found, and this upregulation predicts lower tension than in the control cells). 13 This discrepancy can be explained by an elevated phosphorylation level of the PKC␣-site S26. Thus, the role of S26 in the increased passive stiffness that was revealed in our study of the TAC-induced HF mouse model might be relevant in other diseases as well.
In summary, we found a significant increase in passive myocardial stiffness in HF and that titin plays an important role in this increase. Phosphorylation analysis and PP1 studies identified hyperphosphorylation of S26 of titin as a possible candidate for explaining part of the increased passive stiffness in HF. Lower titin-based stiffness was found in CHF than HF, which might be attributable to the upregulated N2BA titin in CHF compared to HF mice. Thus, altered hemodynamics trigger complex changes in the spring of titin, with hyperphosphorylation of S26 initially causing an increase in passive stiffness, in addition to titin-splicing changes during progression to CHF that lower passive stiffness ( Figure 7B ). Considering that hyperphosphorylation of S26 appears to be a dominant effect in passive stiffness changes during the progression to HF, the PKC pathway warrants further investigation because it is a potential target for therapeutics aimed at lowering diastolic stiffness.
Elucidation of the mechanisms that govern diastolic dysfunction is important for understanding a wide range of cardiac diseases, including HF with preserved ejection fraction. The ECM is often considered to dominate passive myocardial stiffness, but work focused on the intracellular protein titin has shown that titin is also important. We studied diastolic dysfunction and the role of titin in a mouse model of experimental HF. Mechanical studies on skinned LV myocardium showed that total passive stiffness was increased in HF, and this was attributable to increases in both ECM-based and titin-based passive stiffness, with titin being dominant. Although the expression level of titin isoforms were affected, these changes cannot account for the increase in titin stiffness in HF. Investigations into the role of several kinases (protein kinase A and protein kinase C) and phosphatases suggest that the increase in titin-based stiffness could be explained in large part by hyperphosphorylation of titin spring elements. Considering that hyperphosphorylation of ser-26 in the pro-glu-val-lys spring element appears to be an important determinant of changes in passive stiffness during progression to HF, the protein kinase C pathway warrants further investigation because it is a potential target for therapeutics aimed at lowering diastolic stiffness.
